Full text is available at the source.
Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials
Heart health outcomes with SGLT-2 inhibitors and GLP-1 receptor agonists in Asian people with type 2 diabetes
AI simplified
Abstract
A significant reduction in major adverse cardiac events (MACE) was observed with GLP-1 receptor agonists (HR, 0.71; 95% CI, 0.59 to 0.86; P < 0.0001) in Asians.
- No significant reduction in MACE was found with sodium-glucose co-transport-2 inhibitors (HR, 0.88; 95% CI, 0.67 to 1.15; P = 0.35) in Asians.
- There was no significant reduction in heart failure hospitalization or cardiovascular death with SGLT-2Is (HR, 0.86; 95% CI, 0.55 to 1.36; P = 0.53) in Asians.
- The analysis included three CV outcome trials for SGLT-2Is with a total of 4,987 participants and seven trials for GLP-1RAs with 4,298 participants.
- The reasons for the differing outcomes between SGLT-2Is and GLP-1RAs in this population remain unclear and may relate to statistical power or ethnic differences.
AI simplified